Suppr超能文献

其他生殖激素激活素和抑制素对成骨细胞生成和破骨细胞生成的调节。

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.

作者信息

Nicks Kristy M, Perrien Daniel S, Akel Nisreen S, Suva Larry J, Gaddy Dana

机构信息

Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

出版信息

Mol Cell Endocrinol. 2009 Oct 30;310(1-2):11-20. doi: 10.1016/j.mce.2009.07.001. Epub 2009 Jul 15.

Abstract

There is both cellular and physiological evidence demonstrating that both Activins and Inhibins regulate osteoblastogenesis and osteoclastogenesis, and regulate bone mass in vivo. Although Activins and Inhibins were initially isolated from the gonad, Activins are also produced and stored in bone, whereas Inhibins exert their regulation on bone cell differentiation and metabolism via endocrine effects. The accumulating data provide evidence that reproductive hormones, distinct from classical sex steroids, are important regulators of bone mass and bone strength. Given the well described dominant antagonism of Inhibin over Activin, as well as over BMPs and TGFbeta, the gonadally derived Inhibins are important regulators of locally produced osteotrophic factors. Thus, the cycling Inhibins in females and diurnal changes in Inhibin B in males elicit temporal shifts in Inhibin levels (tone) that de-repress the pituitary. This fundamental action has the potential to de-repress locally stimulated changes in osteoblastogenesis and osteoclastogenesis, thereby altering bone metabolism.

摘要

有细胞和生理学证据表明,激活素和抑制素均调节成骨细胞生成和破骨细胞生成,并在体内调节骨量。虽然激活素和抑制素最初是从性腺中分离出来的,但激活素也在骨中产生和储存,而抑制素则通过内分泌作用对骨细胞分化和代谢发挥调节作用。越来越多的数据表明,与经典性类固醇不同的生殖激素是骨量和骨强度的重要调节因子。鉴于抑制素对激活素以及对骨形态发生蛋白(BMPs)和转化生长因子β(TGFbeta)具有明确的显性拮抗作用,性腺来源的抑制素是局部产生的骨营养因子的重要调节因子。因此,女性体内循环的抑制素以及男性体内抑制素B的昼夜变化会引起抑制素水平(基调)的时间性变化,从而解除对垂体的抑制。这一基本作用有可能解除对局部刺激的成骨细胞生成和破骨细胞生成变化的抑制,从而改变骨代谢。

相似文献

1
Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin.
Mol Cell Endocrinol. 2009 Oct 30;310(1-2):11-20. doi: 10.1016/j.mce.2009.07.001. Epub 2009 Jul 15.
3
Mechanisms of inhibin signal transduction.
Recent Prog Horm Res. 2001;56:417-50. doi: 10.1210/rp.56.1.417.
4
Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line.
Endocrinology. 2006 Jul;147(7):3462-71. doi: 10.1210/en.2006-0023. Epub 2006 Apr 6.
5
Properties of inhibin binding to betaglycan, InhBP/p120 and the activin type II receptors.
Mol Cell Endocrinol. 2002 Oct 31;196(1-2):79-93. doi: 10.1016/s0303-7207(02)00227-7.
6
Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.
Mol Cell Endocrinol. 2012 Aug 15;359(1-2):43-52. doi: 10.1016/j.mce.2012.01.025. Epub 2012 Feb 4.
7
Regulation of FSHbeta and GnRH receptor gene expression in activin receptor II knockout male mice.
Mol Cell Endocrinol. 2003 Dec 30;212(1-2):19-27. doi: 10.1016/j.mce.2003.09.019.
8
Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium.
Exp Biol Med (Maywood). 2002 Oct;227(9):724-52. doi: 10.1177/153537020222700905.
9
Activins and inhibins and their signaling.
Ann N Y Acad Sci. 2004 Dec;1038:142-7. doi: 10.1196/annals.1315.023.
10
Targeting activins and inhibins to treat reproductive disorders and cancer cachexia.
J Endocrinol. 2023 Jun 26;258(1). doi: 10.1530/JOE-22-0290. Print 2023 Jul 1.

引用本文的文献

1
Effect of Nanoemulsion Carbonated Hydroxyapatite-Statin Administration on the Alkaline Phosphatase Level during Orthodontic Relapse in Rats.
J Dent (Shiraz). 2025 Sep 1;26(3):250-256. doi: 10.30476/dentjods.2025.103152.2426. eCollection 2025 Sep.
2
Human ectodermal organoids reveal the cellular origin of DiGeorge Syndrome.
bioRxiv. 2025 Aug 8:2025.08.08.669417. doi: 10.1101/2025.08.08.669417.
3
Bone loss induced by cancer treatments in breast and prostate cancer patients.
Clin Transl Oncol. 2022 Nov;24(11):2090-2106. doi: 10.1007/s12094-022-02872-1. Epub 2022 Jul 2.
6
Receptor binding competition: A paradigm for regulating TGF-β family action.
Cytokine Growth Factor Rev. 2021 Feb;57:39-54. doi: 10.1016/j.cytogfr.2020.09.003. Epub 2020 Oct 6.
8
Upregulation of interleukin-8 and activin A induces osteoclastogenesis in ameloblastoma.
Int J Mol Med. 2019 Jun;43(6):2329-2340. doi: 10.3892/ijmm.2019.4171. Epub 2019 Apr 23.
9
Sex Differences in Mouse Popliteal Lymph Nodes.
Sci Rep. 2019 Jan 30;9(1):965. doi: 10.1038/s41598-018-37175-5.
10
Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
J Bone Miner Res. 2018 Oct;33(10):1760-1772. doi: 10.1002/jbmr.3473. Epub 2018 Jun 22.

本文引用的文献

2
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum.
Cell. 2008 Nov 28;135(5):825-37. doi: 10.1016/j.cell.2008.09.059.
3
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7082-7. doi: 10.1073/pnas.0711263105. Epub 2008 May 6.
4
Molecular bases of the sympathetic regulation of bone mass.
Bone. 2008 May;42(5):837-40. doi: 10.1016/j.bone.2008.01.005. Epub 2008 Jan 26.
6
Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.
J Biol Chem. 2008 Mar 21;283(12):7628-37. doi: 10.1074/jbc.M704883200. Epub 2008 Jan 9.
9
The activin A-follistatin system: potent regulator of human extracellular matrix mineralization.
FASEB J. 2007 Sep;21(11):2949-60. doi: 10.1096/fj.07-8080com. Epub 2007 Apr 20.
10
Differential effects of aging on activin A and its binding protein, follistatin, across the menopause transition.
Fertil Steril. 2007 Oct;88(4):1003-5. doi: 10.1016/j.fertnstert.2006.12.009. Epub 2007 Apr 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验